Itrason 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent used for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itrason 200 is indicated for the management of infections caused by dermatophytes, yeasts, and molds, including but not limited to onychomycosis, candidiasis, aspergillosis, histoplasmosis, blastomycosis, and sporotrichosis. The capsule formulation ensures optimal bioavailability when taken with food, as gastric acidity enhances absorption. Dosage and duration of therapy depend on the type and severity of infection, and treatment should be guided by clinical response and susceptibility testing where applicable. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions should be carefully monitored due to itraconazole’s inhibition of CYP3A4 enzymes. Common adverse effects include gastrointestinal disturbances, headache, and rash. Regular liver function monitoring is recommended during prolonged therapy to detect hepatotoxicity early.